SMMT Summit Therapeutics Inc.

BULLISH Impact: 6/10 Insider Cluster (2 insiders)
Horizon weeks Filed Jun 12, 2026 Processed 4d 16h ago
Insider cluster: 2 insiders, $100.0M total
Latest settled — T+1d ⚠ clustered
SMMT ▲ +0.86% at T+1d
LONG call ✓ call won +0.86% · α vs SPY -0.91% · entry $14.01 → $14.13
Next anchor: T+5d in 5d
Currently $13.88 · -0.93% from $14.01 entry
Entry anchored
Jun 12, 02:35 PM ET
via Databento tick
T+1d
+0.86%
call +0.86% · α -0.91%
$14.13
settled yesterday
T+5d
call — · α —
in 5d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Both co-CEOs of Summit Therapeutics (SMMT) each purchased 3.81M shares open-market on June 12, 2026, at $13.12, aggregating ~$100M. This represents ~0.98% of market cap, one of the largest insider buying clusters by dollar value relative to size in the sector. The unanimous C-suite buying signals extreme management conviction, though prior insider cluster predictions on SMMT have underperformed.

Key Financial Metrics

Direction
buying
Total Value
$100.0M
Insiders
2

Actionable Insight

The scale and seniority of this insider buying cluster is a strong signal that management sees material upside from current levels. Traders should watch for near-term clinical data catalysts (ivonescimab trial readouts). However, historical insider cluster calls on SMMT have been negative at T+20, so size positions accordingly and consider a trailing stop.

Key Facts

  • Co-CEOs Robert W. Duggan and Mahkam Zanganeh each purchased 3,810,000 shares on June 12, 2026.
  • Total insider buying value: ~$99.97M at $13.12/share.
  • Total value equals ~0.98% of SMMT's $10.2B market cap.
  • Both purchases were open-market (code P) — not grants or options exercises.
  • The cluster occurred within a 7-day window with no other insider trades.

Financial Impact

~$100M in insider open-market buying, ~0.98% of market cap.

market capownershipinsider sentiment

Risk Factors

  • Biotech clinical trial risk (ivonescimab data may disappoint).
  • Prior insider cluster reports on SMMT showed negative T+20 returns (avg -19%), suggesting this signal may be less reliable for this ticker.
  • The stock already has a $10.2B market cap — limited upside if market has already priced in optimism.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (24 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SMMT-1781289346843
10 reports for SMMT
Performance horizon
0% Hit rate 0 of 4 directional calls best @ T+1▼ −0.23%Jun 9, 2026
Filters
Rows
Reports for SMMT — sortable, filterable
Type Now
Jun 12, 2026
4d ago
Insider Cluster
BULLISH ★ 6/10
$14.01 $14.13▲ +0.86%▼ −0.91%$13.88 (−0.93%)
Jun 12, 2026
4d ago
Institutional Cluster
MIXED ★ 4/10
$14.01 $14.13▲ +0.86%▼ −0.91%$13.88 (−0.93%)
Jun 11, 2026
5d ago
Institutional Cluster
NEUTRAL ★ 3/10
$13.08 $14.01▲ +7.11%▲ +6.57%$13.88 (+6.12%)
Jun 9, 2026
7d ago
S-3ASR
BEARISH ★ 7/10
$13.05 $13.08▼ −0.23%▲ +1.47%$13.88 (−6.36%)
Jun 4, 2026
12d ago
Insider Cluster
BULLISH ★ 5/10
$14.77 $14.11▼ −4.47%▼ −4.69%$13.88 (−6.03%)
Jun 4, 2026
12d ago
Insider Cluster
BULLISH ★ 6/10
$14.77 $14.11▼ −4.47%▼ −4.69%$13.88 (−6.03%)
Jun 3, 2026
13d ago
8-K
NEUTRAL ★ 3/10
$15.07 $14.84▼ −1.53%▼ −1.93%$13.88 (−7.90%)
Jun 1, 2026
15d ago
8-K
BULLISH ★ 7/10
$15.71 $14.86▼ −5.41%▼ −5.56%$13.88 (−11.65%)
Apr 30, 2026
6w ago
8-K
NEUTRAL ★ 5/10
$16.12 $16.98▲ +5.37%▲ +5.71%$13.88 (−13.87%)
Apr 17, 2026
8w ago
DEFA14A
NEUTRAL ★ 2/10
$25.12 $26.38▲ +5.02%▲ +5.67%$13.88 (−44.75%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 2h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access